Clinical data | |
---|---|
Trade names | Nucynta, Palexia, Yantil, others |
Other names | BN-200, CG-5503, R-331333 |
AHFS/Drugs.com | Monograph |
MedlinePlus | a610006 |
Pregnancy category |
|
Addiction liability | High[1] |
Routes of administration | By mouth[1] |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 32% (by mouth)[2] |
Protein binding | 20%[3] |
Metabolism | Liver (mostly via glucuronidation but also by CYP2C9, CYP2C19, CYP2D6)[2] |
Onset of action | 30 min[4] |
Elimination half-life | 4 hours< (duration 4-6 hours)[2] |
Duration of action | 4 to 6 hr[5] |
Excretion | Urine and feces (1%)[2] |
Identifiers | |
| |
Chemical and physical data | |
Formula | C14H23NO |
Molar mass | 221.344 g·mol−1 |
3D model (JSmol) | |
Boiling point | (decomposes) |
| |
| |
(what is this?) (verify) |
Tapentadol, sold under the brand names Nucynta among others, is an opioid pain medication.[1] It may be used for moderate to severe pain of short or long duration.[1][6] It is taken by mouth.[1] Onset occurs in about 30 minutes and lasts for 4–6 hours.[4][5]
Common side effects include nausea, sleepiness, constipation, and itchiness.[1] Other side effects may include seizures, low blood pressure, addiction, serotonin syndrome, and insufficient breathing (respiratory depression).[1] Use during pregnancy may harm the baby.[1] Risk of misuse is similar to other strong opioids.[1] While how it works is not entirely clear, it acts on the μ-opioid receptor and increases both serotonin and norepinephrine levels.[1]
Tapentadol was approved for medical use in the United States in 2008,[1] Australia in 2010,[7] and in the UK and India in 2011.[8][9] In the United States it costs about 230 USD for 30 tablets of 50 mg immediate release formulation as of 2021.[10] This amount in the United Kingdom costs the NHS about £15.[6] It also comes in a slow release formulation.[6]
References
edit- ^ a b c d e f g h i j k l m n "Tapentadol Monograph for Professionals". Drugs.com. Archived from the original on 5 March 2021. Retrieved 22 September 2021.
- ^ a b c d Fidman, B; Nogid, A (2010). "Role of Tapentadol Immediate Release (Nucynta) in the Management Of Moderate-to-Severe Pain". Pharmacy and Therapeutics. 35 (6): 330–357. PMC 2888545.
- ^ Brayfield, A, ed. (14 November 2011). "Tapentadol". Martindale: The Complete Drug Reference. Pharmaceutical Press. Archived from the original on 29 August 2021. Retrieved 2 April 2014.
- ^ a b Emmett, Stevan R.; Hill, Nicola; Dajas-Bailador, Federico (30 October 2019). Clinical Pharmacology for Prescribing. Oxford University Press. p. 441. ISBN 978-0-19-258564-6. Archived from the original on 22 September 2021. Retrieved 22 September 2021.
- ^ a b Fischer, János; Ganellin, C. Robin; Rotella, David P. (15 October 2012). Analogue-based Drug Discovery III. John Wiley & Sons. p. 44. ISBN 978-3-527-65110-8. Archived from the original on 22 September 2021. Retrieved 22 September 2021.
- ^ a b c d BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 491. ISBN 978-0-85711-369-6.
{{cite book}}
: CS1 maint: date format (link) - ^ "TGA eBS - Product and Consumer Medicine Information Licence". www.ebs.tga.gov.au. Archived from the original on 30 March 2020. Retrieved 22 September 2021.
- ^ "Palexia film coated tablets". electronic Medicines Compendium. Grunenthal Ltd. 13 November 2013. Archived from the original on 7 April 2014. Retrieved 2 April 2014.
- ^ Mukherjee, Diptadhi; Shukla, Lekhansh; Saha, Priyanka; Mahadevan, Jayant; Kandasamy, Arun; Chand, Prabhat; Benegal, Vivek; Murthy, Pratima (March 2020). "Tapentadol abuse and dependence in India". Asian Journal of Psychiatry. 49: 101978. doi:10.1016/j.ajp.2020.101978. PMID 32120298.
- ^ "Nucynta Prices, Coupons & Savings Tips - GoodRx". GoodRx. Archived from the original on 10 March 2021. Retrieved 22 September 2021.